Video

ASCO 2011 Annual Meeting Picture Slideshow Day Four

Author(s):

Onclive Team
Conference|ASCO Annual Meeting

American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four

American Society of Clinical Oncology (ASCO) 2011 annual meeting picture slideshow day four

Related Videos
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Sumanta Kumar Pal, MD, FASCO,
Stephen V. Liu, MD
Related Content
María-Victoria Mateos, MD, PhD, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer
June 2nd 2024

Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma

Arndt Vogel, MD
June 2nd 2024

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Frederik Marmé, MD, PhD, of the University of Heidelberg
June 2nd 2024

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

Rene Adam, MD, PhD
June 2nd 2024

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

Sayed Matar, MBBChB, of Brigham and Women’s Hospital
June 2nd 2024

mIF Biomarker Not Associated With Improved Outcomes With Nivolumab/Ipilimumab Treatment in Metastatic Clear Cell RCC

Taletrectinib in ROS1-positive non–small cell lung cancer: © stock.adobe.com
June 2nd 2024

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC